

# World Journal of *Cardiology*

*World J Cardiol* 2013 January 26; 5(1): 1-7



## Editorial Board

2009-2013

The *World Journal of Cardiology* Editorial Board consists of 362 members, representing a team of worldwide experts in cardiology. They are from 43 countries, including Argentina (4), Australia (9), Belgium (2), Brazil (5), Canada (24), Chile (1), China (18), Colombia (1), Czech (1), Denmark (4), France (3), Germany (32), Greece (14), Hungary (2), India (8), Iran (2), Ireland (1), Israel (2), Italy (44), Japan (24), Kosovo (1), Lebanon(1), Malaysia (1), Mexico (1), Morocco (1), Netherlands (9), Nigeria (1), Oman (1), Pakistan (1), Poland (3), Portugal (1), Russia (1), Singapore (1), Slovenia (2), South Africa (2), South Korea (6), Spain (10), Switzerland (1), Thailand (1), Turkey (8), United Kingdom (14), United States (93), and Uruguay (1).

### EDITOR-IN-CHIEF

Raúl Moreno, *Madrid*  
Victor L Serebruany, *Baltimore*

### STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Amitesh Aggarwal, *Delhi*  
Imtiaz S Ali, *Halifax*  
Giuseppe Biondi-Zoccai, *Turin*  
AC Campos de Carvalho, *Rio de Janeiro*  
Serafino Fazio, *Naples*  
Steven Joseph Haas, *Melbourne*  
Masoor Kamlesh, *Indianapolis*  
Peter A McCullough, *Royal Oak*  
Giuseppe Mulé, *Palermo*  
Mamas A Mamas, *Manchester*  
Shinro Matsuo, *Kanazawa*  
Prashanth Panduranga, *Muscat*  
Rui A Providência, *Coimbra*  
Seung-Woon Rha, *Seoul*  
Manel Sabaté, *Barcelona*  
SAM Said, *Hengelo*

### GUEST EDITORIAL BOARD MEMBERS

Shih-Tai Chang, *Chua-Yi Shien*  
Mien-Cheng Chen, *Kaohsiung*  
Ming-Jui Hung, *Keelung*  
Pi-Chang Lee, *Taipei*  
Hung-Jung Lin, *Tainan*  
Shoa-Lin Lin, *Kaohsiung*  
Chin-San Liu, *Changhua*  
Wei-Chuan Tsai, *Tainan*  
Chin-Hsiao Tseng, *Taipei*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

Tomás F Cianciulli, *Buenos Aires*

José Milei, *Buenos Aires*  
Alfredo E Rodriguez, *Buenos Aires*  
Gaston A Rodriguez-Granillo, *Buenos Aires*



#### Australia

Yuri V Bobryshev, *Kensington*  
Gavin Lambert, *Melbourne*  
Peter J Little, *Melbourne*  
Ralph Nigel Martins, *Nedlands*  
Trevor A Mori, *Perth*  
Jason N Peart, *Brisbane*  
Joseph B Selvanayagam, *Adelaide*  
Zhonghua Sun, *Perth*



#### Belgium

Bernhard L Gerber, *Woluwe St. Lambert*  
Paul Vermeersch, *Antwerp*



#### Brazil

Luiz César Guarita-Souza, *Curitiba Pr*  
CA Mandarim-de-Lacerda, *Rio de Janeiro*  
Cristiane Pulz, *Code*  
Jose E Tanus-Santos, *Ribeirao Preto*



#### Canada

Rodrigo Bagur, *Quebec*  
Olivier F Bertrand, *Quebec*  
MG Bourassa, *Quebec*  
Mohamed Chahine, *Québec*  
Michael CY Chan, *Edmonton*  
Clara Chow, *Sydney*  
Paul Farand, *Sherbrooke*  
R Michael Giuffre, *Alberta*  
Haissam Haddad, *Ontario*

Pavel Hamet, *Québec*  
Francois Harel, *Montreal*  
Ismail Laher, *Vancouver*  
Frans HH Leenen, *Ontario*  
Gordon Moe, *Ontario*  
Kambiz Norozi, *London*  
Louis P Perrault, *Quebec*  
Philippe Pibarot, *Quebec*  
Shirya Rashid, *Hamilton*  
Robert Roberts, *Ottawa*  
Grzegorz Sawicki, *Saskatoon*  
Chantale Simard, *Québec*  
Jack CJ Sun, *Hamilton*  
Anthony S Tang, *Victoria*



#### Chile

Xavier F Figueroa, *Santiago*



#### China

Shao-Liang Chen, *Nanjing*  
Lan Huang, *Chongqing*  
En-Zhi Jia, *Nanjing*  
Bin Jiang, *Beijing*  
Man-Hong Jim, *Hong Kong*  
Jian-Jun Li, *Beijing*  
Tong Liu, *Tianjin*  
Yong Xu, *Nanjing*  
Xiao-Ming Zhang, *Hangzhou*



#### Colombia

Patricio Lopez-Jaramillo, *Santander*



#### Czech

Jan Sochman, *Prague*

**Denmark**

Morten Grunnet, *Ballerup*  
 Won Yong Kim, *Aarhus*  
 Ole Dyg Pedersen, *Copenhagen*  
 Jacob Tfelt-Hansen, *Copenhagen*

**France**

Philippe Commeau, *Ollioules*  
 Yves D Durandy, *Massy*  
 Thierry Lefèvre, *Massy*

**Germany**

Ferruh Artunc, *Tübingen*  
 Muhammet A Aydin, *Hamburg*  
 Alexander Bauer, *Heidelberg*  
 Peter Bernhardt, *Ulm*  
 Torsten Bossert, *Jena*  
 Marcus Dörr, *Greifswald*  
 Holger Eggebrecht, *Essen*  
 Tommaso Gori, *Mainz*  
 Dariusch Haghi, *Mannheim*  
 Stefan E Hardt, *Heidelberg*  
 Klaus Hertting, *Hamburg*  
 Thomas Jax, *Neuss*  
 Thorsten Kälsch, *Mannheim*  
 Klaus Kettering, *Frankfurt*  
 Grigorios Korosoglou, *Heidelberg*  
 Horst J Kuhn, *Planegg*  
 Lorenz H Lehmann, *Heidelberg*  
 Huige Li, *Mainz*  
 Veselin Mitrovic, *Bad Nauheim*  
 Ulrich Nellessen, *Stendal*  
 Guenter Pilz, *Hausham*  
 Peter W Radke, *Lübeck*  
 Obaida Rana, *Aachen*  
 Tienush Rassaf, *Düsseldorf*  
 Oliver Ritter, *Wuerzburg*  
 Erol Saygili, *Aachen*  
 Dirk Skowasch, *Bonn*  
 Tim Süselbeck, *Mannheim*  
 Dirk Taubert, *Cologne*  
 Theodor Tirilomis, *Goettingen*  
 Stephen Wildhirt, *Ulm*  
 Thomas Zeller, *Bad Krozingen*

**Greece**

Yiannis S Chatzizisis, *Thessaloniki*  
 Moses S Elisaf, *Ioannina*  
 Gerasimos Filippatos, *Athens*  
 Panagiotis Korantzopoulos, *Ioannina*  
 Nicholas G Kounis, *Patras*  
 Antigone Lazou, *Thessaloniki*  
 Konstantinos P Letsas, *Athens*  
 Athanassios N Manginas, *Athens*  
 Lampros Michalis, *Ioannina*  
 Serafim Nanas, *Athens*  
 Loukianos S Rallidis, *Athens*  
 Georgios I Tagarakis, *Thessaloniki*  
 Dimitrios Tziakas, *Alexandroupolis*  
 Theodoros Xanthos, *Athens*

**Hungary**

Gergely Feher, *Pecs*

Albert Varga, *Szeged*

**India**

MPS Chawla, *Roorkee*  
 S Dwivedi, *Delhi*  
 Rajeev Gupta, *Jaipur*  
 Deepak Kaul, *Chandigarh*  
 Prabhakaran Prabhakaran, *New Delhi*  
 KV Pugalendi, *Tamilnadu*  
 Rajesh Vijayvergiya, *Chandigarh*

**Iran**

VR Dabbagh Kakhki, *Mashhad*  
 Roya Kelishadi, *Isfahan*

**Ireland**

Jonathan D Dodd, *Dublin*

**Israel**

Jacob George, *Tel Aviv*  
 E Goldhammer, *Haifa*

**Italy**

Maria Grazia Andreassi, *Massa*  
 Giuseppe Barbaro, *Rome*  
 Riccardo Bigi, *Milan*  
 Tonino Bombardini, *Pisa*  
 Filippo Cademartiri, *Parma*  
 Alessandro Capucci, *Piacenza*  
 Sergio Coccheri, *Bologna*  
 Antonio Colombo, *Milan*  
 Alberto Cuocolo, *Napoli*  
 Roberto De Ponti, *Varese*  
 Gianluca Di Bella, *Messina*  
 Giovanni Fazio, *Palermo*  
 Vittorio Fineschi, *Foggia*  
 Antonio F Folino, *Padova*  
 Gabriele Fragasso, *Milano*  
 Carmine Gazzaruso, *Vigevano*  
 Massimo Imazio, *Torino*  
 Federico Lombardi, *Milan*  
 Roberto Marchioli, *Santa Maria Imbaro*  
 Giovan Giuseppe Mattera, *Pomezia*  
 Germano Melissano, *Milano*  
 Pietro A Modesti, *Florence*  
 Eraldo Occhetta, *Novara*  
 Pasquale Pagliaro, *Orbassano*  
 Emilio Maria G Pasanisi, *Pisa*  
 Vincenzo Pasceri, *Rome*  
 Salvatore Patanè, *Messina*  
 Nunzia Rosa Petix, *Florence*  
 Eugenio Picano, *Pisa*  
 Rita Rezzani, *Brescia*  
 Manfredi Rizzo, *Palermo*  
 Gian Paolo Rossi, *Padua*  
 Speranza Rubattu, *Rome*  
 Andrea Rubboli, *Bologna*  
 Rosa Sicari, *Pisa*  
 Giuseppe Tarantini, *Padua*  
 Luigi Tavazzi, *Cotignola*  
 Luca Testa, *Milan*  
 Maurizio Turiel, *Milan*  
 Cristina Vassalle, *Pisa*  
 Massimo Volpe, *Rome*

**Japan**

Yoshifusa Aizawa, *Niigata*  
 Junichiro Hashimoto, *Sendai*  
 Hajime Kataoka, *Oita*  
 Akinori Kimura, *Tokyo*  
 Sei Komatsu, *Amagasaki*  
 Ikuo Fukuda, *Hirosaki*  
 Satoshi Kurisu, *Hiroshima*  
 Yoshihiro Matsumoto, *Shizuoka*  
 Tetsuo Minamino, *Osaka*  
 Yoko Miyasaka, *Osaka*  
 Kenichi Nakajima, *Kanazawa*  
 Mashio Nakamura, *Tsu*  
 Kazuaki Nishio, *Tokyo*  
 Koichi Sakabe, *Kagawa*  
 Masataka Sata, *Tokushima*  
 Shinji Satoh, *Fukuoka*  
 Yoshihide Takahashi, *Kanagawa*  
 Masamichi Takano, *Chiba*  
 Kengo Tanabe, *Tokyo*  
 Hiroki Teragawa, *Hiroshima*  
 Hiroyasu Ueda, *Osaka*  
 Takanori Yasu, *Okinawa*  
 Hiroshi Yoshida, *Chiba*

**Kosovo**

Gani Bajraktari, *Prishtina*

**Lebanon**

Habib A Dakik, *Beirut*

**Malaysia**

Eric Tien Siang Lim, *Johor*

**Mexico**

Enrique Vallejo, *Mexico*

**Morocco**

Abdenasser Drighil, *Casablanca*

**Netherlands**

Folkert Wouter Asselbergs, *Groningen*  
 Jeroen J Bax, *Leiden*  
 JJ Brugts, *Rotterdam*  
 Peter W de Leeuw, *AZ Maastricht*  
 Corstiaan A Den Uil, *Rotterdam*  
 PA Doevendans, *Utrecht*  
 D Poldermans, *Rotterdam*  
 PW Serruys, *Rotterdam*

**Nigeria**

OS Ogah, *Ibadan*

**Pakistan**

Fahim H Jafary, *Karachi*

**Poland**

Pawel Buszman, *Katowice*  
 Maciej Kurpisz, *Poznan*  
 Sebastian Szmít, *Warsaw*

**Russia**

Nadezda Bylova, *Moscow*

**Singapore**

Jinsong Bian, *Singapore*

**Slovenia**

Mitja Lainscak, *Golnik*  
 Matej Podbregar, *Ljubljana*

**South Africa**

Benjamin Longo-Mbenza, *Pretoria*  
 JP Smedema, *Capetown*

**South Korea**

Jang-Ho Bae, *Daejeon*  
 Young-Guk Ko, *Seoul*  
 Sang-Hak Lee, *Seoul*  
 Pil-Ki Min, *Seoul*  
 Seung-Jung Park, *Seoul*

**Spain**

Miguel A Arias, *Toledo*  
 Antoni Bayés-Genís, *Barcelona*  
 Alberto Dominguez-Rodriguez, *Tenerife*  
 Lorenzo Facila, *Castellon*  
 José Luis Pérez-Castrillon, *Valladolid*  
 Jesus Peteiro, *Coruña*  
 Pedro L Sánchez, *Madrid*  
 José L Zamorano, *Madrid*

**Switzerland**

Paul Erne, *Luzern*

**Thailand**

Nipon Chattipakorn, *Chiang Mai*

**Turkey**

Turgay Çelik, *Etilik-Ankara*

Yengi U Celikyurt, *Kocaeli*  
 Hamza Duygu, *Yesilyurt*  
 Cemil Gürkün, *İzmir*  
 T Fikret İlgenli, *Kocaeli*  
 Ergün Barış Kaya, *Ankara*  
 Mehmet Ozaydin, *Isparta*  
 Mustafa Yildiz, *Istanbul*

**United Kingdom**

AD Blann, *Birmingham*  
 Geoffrey Burnstock, *London*  
 John GF Cleland, *Kingston upon Hull*  
 Armen Yuri Gasparyan, *Dudley*  
 Derek J Hausenloy, *London*  
 Farhad Kamali, *Newcastle upon Tyne*  
 Juan Carlos Kaski, *London*  
 Rajesh G Katare, *Bristol*  
 Sohail Q Khan, *Manchester*  
 Khalid Rahman, *Liverpool*  
 Alexander M Seifalian, *London*  
 Mark Slevin, *Manchester*  
 Anastasis Stephanou, *London*

**United States**

Kamran Akram, *Omaha*  
 Arshad Ali, *Ashland*  
 Mouaz Al-Mallah, *Detroit*  
 Naser M Ammash, *Rochester*  
 Vignendra Ariyarajah, *Philadelphia*  
 Wilbert S Aronow, *Vallhalla*  
 S Serge Barold, *Tampa*  
 Gregory W Barsness, *Rochester*  
 Daniel S Berman, *Los Angeles*  
 John F Beshai, *Chicago*  
 William E Boden, *Buffalo*  
 Somjot S Brar, *Los Angeles*  
 David W Brown, *Decatur*  
 Lu Cai, *Louisville*  
 Christopher Paul Cannon, *Boston*  
 Ricardo Castillo, *Brooklyn*  
 Jun R Chiong, *Loma Linda*  
 Steven G Chrysant, *Oklahoma*  
 Timm Dickfeld, *Baltimore*  
 Dayue Darrel Duan, *Reno*  
 Rosemary B Duda, *Boston*  
 Michael E Farkouh, *New York*  
 Arthur Michael Feldman, *Philadelphia*  
 Ronald Freudenberger, *Allentown*  
 Jalal K Ghali, *Detroit*  
 Lev G Goldfarb, *Bethesda*  
 Samuel Z Goldhaber, *Boston*  
 Hitinder S Gurm, *Ann Arbor*  
 Julia H Indik, *Tucson*  
 Antony Leslie Innasimuthu, *Pittsburgh*  
 Ami E Iskandrian, *Birmingham*  
 Rovshan M Ismailov, *Pittsburgh*  
 Diwakar Jain, *Philadelphia*  
 Shahrokh Javaheri, *Mason*

Jacob Joseph, *West Roxbury*  
 Bobby V Khan, *Atlanta*  
 Christopher M Kramer, *Charlottesville*  
 Rakesh C Kukreja, *Richmond*  
 Roberto M Lang, *Chicago*  
 Marzia Leacche, *Nashville*  
 Jingping Lin, *Bethesda*  
 Yi-Hwa Liu, *New Haven*  
 Angel López-Candales, *Pittsburgh*  
 Frank Marcus, *Tucson*  
 Malek G Massad, *Chicago*  
 Jawahar L Mehta, *Little Rock*  
 Robert M Mentzer Jr, *Detroit*  
 J Gary Meszaros, *Rootstown*  
 Michael Miller, *Baltimore*  
 Emile R Mohler III, *Philadelphia*  
 Patrick M Moriarty, *Kansas City*  
 Jeffrey W Moses, *New York*  
 Mohammad-Reza Movahed, *Tucson*  
 Gerald V Naccarelli, *Hershey*  
 Andrea Natale, *Austin*  
 Tien MH Ng, *Los Angeles*  
 Steven Nissen, *Cleveland*  
 Gian M Novaro, *Weston*  
 Brian Olshansky, *Iowa*  
 Robert Lee Page II, *Aurora*  
 Weihong Pan, *Baton Rouge*  
 Linda Pauliks, *Hershey*  
 Philip Jack Podrid, *Boston*  
 Vikas K Rathi, *Midlothian*  
 Jun Ren, *Laramie*  
 Harmony R Reynolds, *New York*  
 Clive Rosendorff, *Bronx*  
 Samir Saba, *Pittsburgh*  
 Rajesh Sachdeva, *Little Rock*  
 Sandeep A Saha, *Spokane*  
 Tiziano M Scarabelli, *Detroit*  
 Robert H Schneider, *Maharishi Vedic*  
 Frank W Sellke, *Providence*  
 Samin K Sharma, *New York*  
 Jamshid Shirani, *Danville*  
 Boris Z Simkhovich, *Los Angeles*  
 Krishna Singh, *Johnson City*  
 Laurence S Sperlíng, *Atlanta*  
 Jonathan S Steinberg, *New York*  
 Ernst R von Schwarz, *Los Angeles*  
 Richard Gary Trohman, *Chicago*  
 Tong Tang, *San Diego*  
 Qing Kenneth Wang, *Cleveland*  
 Yi Wang, *Wilmington*  
 Adam Whaley-Connell, *Columbia*  
 Bruce L Wilkoff, *Cleveland*  
 Qinglin Yang, *Birmingham*  
 Xing Sheng Yang, *Atlanta*  
 Yucheng Yao, *Los Angeles*  
 Midori A Yenari, *San Francisco*  
 Cuihua Zhang, *Columbia*

**Uruguay**

Juan C Grignola, *Montevideo*



**BRIEF ARTICLE**

- 1 Evaluation of coronary microvascular function in patients with vasospastic angina

*Teragawa H, Mitsuba N, Ishibashi K, Nishioka K, Kurisu S, Kihara Y*

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** Editorial Board Member of *World Journal of Cardiology*, Seung-Woon Rha, MD, PhD, FACC, FAHA, FESC, FSCAI, FAPSIC, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, South Korea

**AIM AND SCOPE** *World Journal of Cardiology (World J Cardiol, WJC)*, online ISSN 1949-8462, DOI: 10.4330 is a peer-reviewed open access journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJC* covers topics concerning arrhythmia, heart failure, vascular disease, stroke, hypertension, prevention and epidemiology, dyslipidemia and metabolic disorders, cardiac imaging, pediatrics, nursing, and health promotion. Priority publication will be given to articles concerning diagnosis and treatment of cardiology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJC*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ ABSTRACTING** *World Journal of Cardiology* is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

**FLYLEAF** I-III Editorial Board

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Shuai Ma* Responsible Science Editor: *Huan-Huan Zhai*  
Responsible Electronic Editor: *Dan-Ni Zhang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

**NAME OF JOURNAL**  
*World Journal of Cardiology*

**ISSN**  
ISSN 1949-8462 (online)

**LAUNCH DATE**  
December 31, 2009

**FREQUENCY**  
Monthly

**EDITOR-IN-CHIEF**  
**Raúl Moreno, MD, Director** of Interventional Cardiology, Interventional Cardiology, Hospital La Paz, Paseo La Castellana, 261, 28041 Madrid, Spain

**Victor L Serebruany, MD, PhD, Associate Professor**, Johns Hopkins University School of Medicine, President, HeartDrug™ Research Laboratories, Osler Medical Center, 7600 Osler Drive, Suite 307, Towson, MD 21204, United States

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Cardiology*  
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjc@wjgnet.com](mailto:wjc@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building, No.90 Jaffe Road, Wanchai, Hong Kong, China  
Telephone: +852-31158812  
Fax: +852-31158812  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
January 26, 2013

**COPYRIGHT**  
© 2013 Baishideng. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/1949-8462/g\\_info\\_20100316161927.htm](http://www.wjgnet.com/1949-8462/g_info_20100316161927.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>

## Evaluation of coronary microvascular function in patients with vasospastic angina

Hiroki Teragawa, Naoya Mitsuba, Ken Ishibashi, Kenji Nishioka, Satoshi Kurisu, Yasuki Kihara

Hiroki Teragawa, Department of Cardiovascular Medicine, Hiroshima General Hospital of West Japan Railway Company, Hiroshima 732-0057, Japan

Naoya Mitsuba, Ken Ishibashi, Kenji Nishioka, Satoshi Kurisu, Yasuki Kihara, Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima 734-8551, Japan

**Author contributions:** Teragawa H designed the study, collected data and wrote the manuscript; Mitsuba N, Ishibashi K and Nishioka K collected data; Kurisu S evaluated the study data; Kihara Y approved the final version of the manuscript.

**Correspondence to:** Hiroki Teragawa, MD, PhD, Department of Cardiovascular Medicine, Hiroshima General Hospital of West Japan Railway Company, 3-1-36 Futabanosato, Higashi-ku, Hiroshima 732-0057, Japan. [hiroteraga71@gmail.com](mailto:hiroteraga71@gmail.com)

Telephone: +81-82-2621171 Fax: +81-82-2621499

Received: September 10, 2012 Revised: December 24, 2012

Accepted: January 5, 2013

Published online: January 26, 2013

### Abstract

**AIM:** To investigate endothelium-dependent and -independent coronary microvascular functions in patients with vasospastic angina (VSA).

**METHODS:** Thirty-six patients with VSA (30 men and 6 women; mean age, 58 years) were enrolled in this study. VSA was defined as  $\geq 90\%$  narrowing of the epicardial coronary arteries on angiography performed during a spasm provocation test, presence of chest pain, and/or ST-segment deviation on an electrocardiogram (ECG). Patients ( $n = 36$ ) with negative spasm provocation test results and those matched for age and sex were enrolled as a control group (nonVSA group). Low-dose acetylcholine (ACh;  $3 \mu\text{g}/\text{min}$ ) was infused into the left coronary ostium for 2 min during the spasm provocation test. Following the spasm provocation test, nitroglycerin (0.2 mg) was administered intracoronally. Coronary blood flow (was calculated from quantitative

angiography and Doppler flow velocity measurements, and the coronary flow reserve was calculated as the ratio of coronary flow velocity after injection of adenosine triphosphate ( $20 \mu\text{g}$ ) to the baseline value. Changes in the coronary artery diameter in response to ACh and nitroglycerin infusion were expressed as percentage changes from baseline measurements.

**RESULTS:** Body mass index was significantly lower in the VSA group than in the nonVSA group. The frequency of conventional coronary risk factors and the rate of statin use were similar between the 2 groups. The left ventricular ejection fraction as evaluated by echocardiography was similar between the 2 groups. The duration of angina was  $9 \pm 2$  mo. The results of blood chemistry analysis were similar between the 2 groups. Low-dose ACh did not cause coronary spasms. The change in coronary artery diameter in response to ACh was lower in the VSA group ( $-1.4\% \pm 9.3\%$ ) than in the nonVSA group ( $3.1\% \pm 6.5\%$ ,  $P < 0.05$ ), whereas nitroglycerin-induced coronary artery dilatation and coronary blood flow increase in response to ACh or coronary flow reserve did not differ significantly between the 2 groups.

**CONCLUSION:** These findings suggest that microvascular coronary function may be preserved despite endothelial dysfunction of the epicardial coronary arteries in patients with VSA.

© 2013 Baishideng. All rights reserved.

**Key words:** Coronary spasm; Endothelial function; Acetylcholine

Teragawa H, Mitsuba N, Ishibashi K, Nishioka K, Kurisu S, Kihara Y. Evaluation of coronary microvascular function in patients with vasospastic angina. *World J Cardiol* 2013; 5(1): 1-7 Available from: URL: <http://www.wjgnet.com/1949-8462/full/v5/i1/1.htm> DOI: <http://dx.doi.org/10.4330/wjc.v5.i1.1>

## INTRODUCTION

Vasospastic angina (VSA) is characterized by coronary spasms, which occur because of a dynamic, transient decrease in the luminal diameter of epicardial coronary arteries due to increased vasomotor tone, ultimately leading to myocardial ischemia<sup>[1,2]</sup>. Abnormal vascular functions of the epicardial coronary arteries, including endothelial dysfunction<sup>[3,4]</sup> and vascular smooth muscle dysfunction<sup>[5-7]</sup>, play pivotal roles in VSA pathogenesis. However, there are few studies that have investigated coronary microvascular function in patients with VSA<sup>[8-12]</sup>. Therefore, to confirm the presence of coronary microvascular dysfunction in patients with VSA, we investigated their endothelium-dependent and -independent coronary microvascular functions and compared the results with those of patients without VSA.

## MATERIALS AND METHODS

### Study population

Thirty-six patients with VSA (VSA group; 30 males and 6 females; mean age, 58 years) diagnosed by a positive spasm provocation test and another 36 patients with negative results of the spasm provocation test performed for the evaluation of chest symptoms (nonVSA group) were enrolled in this study. The 2 groups were well matched with respect to age and sex. Patients with organic coronary stenosis (> 50%), history of myocardial infarction, cardiomyopathy, heart failure, or any other serious medical condition were excluded from the study. Written informed consent was obtained from all patients prior to the study. The protocol was approved by the Ethics Committee of our institution.

### Study protocol

All antianginal agents were discontinued at least 48 h prior to catheterization with the exception of sublingual nitroglycerin (NTG), which was withheld for 1 h prior to catheterization. Diagnostic left heart catheterization and coronary angiography were performed using a standard percutaneous brachial approach. A 6F guide catheter was introduced into the left main coronary artery. A 0.0014 Doppler flow guidewire (Volcano FloWire; Volcano Therapeutics Inc., Rancho Cordova, CA, United States) was advanced through the guide catheter into the proximal segment of the left anterior descending coronary artery (LAD). The wire tip was positioned in a straight segment of the vessel to obtain a reliable flow velocity signal.

After baseline control conditions were established, incremental doses (3 and 30  $\mu\text{g}/\text{min}$ ) of acetylcholine (ACh) were infused into the left coronary artery for 2 min, with 5-min intervals between consecutive doses. If a coronary spasm was not induced by ACh, incremental doses of methylethylgometriner maleate (EM) were infused into the left coronary artery (10, 20, and 30  $\mu\text{g}/\text{min}$ ) for 1 min, with 1-min intervals between consecutive doses. If coronary spasms were not induced by this infusion

also, incremental doses (15 and 25  $\mu\text{g}/\text{min}$ ) of EM were infused into the right coronary artery following the same protocol as that followed for the left coronary artery. When coronary spasms were induced or EM infusion was discontinued, because coronary spasms were not provoked, NTG (200  $\mu\text{g}$ ) was administered by intracoronary injection. Intracoronary ACh and EM were administered using an infusion pump (TE-311; Terumo, Tokyo, Japan) at a rate of 1 mL/min. Coronary angiography was performed immediately after the appearance of chest symptoms and/or ST segment changes after each dose of ACh administration, after the last dose of EM when neither chest symptoms nor ST segment changes were induced, or 2 min after NTG injection. Finally, adenosine triphosphate (20  $\mu\text{g}$ ) was infused into the left coronary artery. Coronary blood flow (CBF) velocity was monitored continuously using a 12-MHz pulsed Doppler velocimeter (FloMap; Volcano Therapeutics Inc.). Arterial pressure, heart rate, and electrocardiography (ECG) readings were monitored continuously and recorded using a multichannel recorder (Polygraph 1600; Nihon Electric Corporation, Tokyo, Japan).

### Quantitative coronary angiography

A method for measuring the coronary artery diameter has been described previously<sup>[13-16]</sup>. The coronary segment 2 mm distal to the Doppler wire tip, which was not the spastic segment was selected for quantitative analysis. For each patient, luminal diameters of the selected LAD segments were measured by a single investigator blinded to the clinical data, using an end-diastolic frame by a computer-assisted coronary angiographic analysis system (CAAS II/QUANTCOR; Siemens, Berlin, Germany). Measurements were performed 3 times, and the average value was used for analysis. Changes in coronary artery diameter in response to ACh and NTG infusion were expressed as percentage changes from baseline angiographic measurements obtained before infusion. Intraobserver and interobserver variability of this method were previously shown to be excellent<sup>[17]</sup>.

### Estimation of CBF and coronary flow reserve

Coronary flow reserve (CFR) was calculated as the product of CBF velocity and vessel diameter using the following formula:  $\pi \times \text{average peak velocity} \times 0.125 \times \text{diameter}^2$ . For CBF calculations, the internal diameter of the vessel at the location of the flow measurements (2 mm distal to the wire tip) was measured using the method described above. CFR was calculated as the ratio of CBF velocity after adenosine triphosphate infusion to the baseline velocity.

### Definitions

VSA was defined as  $\geq 90\%$  narrowing of the epicardial coronary arteries on angiography performed during the spasm provocation test, presence of characteristic chest pain, and/or ST-segment deviation on ECG<sup>[18]</sup>. The LAD trunk was divided into proximal, middle, and distal segments of equal lengths. The location of the spastic

**Table 1** Patients' characteristics (mean  $\pm$  SD) *n* (%)

	NonVSA group ( <i>n</i> = 36)	VSA group ( <i>n</i> = 36)	<i>P</i> value
Age (yr)	60 $\pm$ 9	59 $\pm$ 9	NS
Male/female	31/5	30/6	NS
Body mass index (kg/m <sup>2</sup> )	25.2 $\pm$ 3.2	23.2 $\pm$ 2.6	0.0045
Coronary risk facto			
Smoking	25 (69)	24 (67)	NS
Current/passt smoker	11/13	12/13	NS
Hypertension	21 (58)	19 (53)	NS
Dyslipidemia	11 (31)	11 (31)	NS
Diabetes mellitus	9 (25)	4 (11)	NS
Taking statins (%)	4 (11)	3 (9)	NS
LVEF on echocardiography (%)	71 $\pm$ 8	68 $\pm$ 7	NS

VSA: Vasospastic angina; NS: Not significant; LVEF: Left ventricular ejection fraction.

segment is expressed with reference to these 3 segments. When coronary spasms occurred diffusely from the proximal to the distal segment, the location was defined as proximal, middle, and distal. A diffuse spasm was defined as that when the length of the spastic segment was  $\geq$  20 mm, and a focal spasm was defined as that when the length of the spastic segment was  $<$  20 mm. A totally occluded spastic segment was also considered to represent a diffuse spasm. In the present study, coronary spasms occurred in all LADs and also in the left circumflex coronary artery in some VSA patients (multivessel spasm). The duration of angina was obtained from the patients' medical examinations performed *via* interviews.

As described previously<sup>[14,17,19-21]</sup>, in the present study, we adopted the percent changes in epicardial coronary diameter in response to ACh and NTG infusions as the endothelium-dependent and -independent functions of the coronary artery at the level of conduit vessels, and adopted the percent change in CBF in response to ACh infusion and CFR as the endothelium-dependent and -independent functions of the coronary artery at the level of resistance vessels.

#### Biochemical markers and assessment of coronary risk factors

Fasting blood samples were obtained on the same day of coronary angiography. The patients were questioned about their smoking status and classified as a current smoker, past smoker (who had stopped smoking for at least 1 mo), or nonsmoker. Blood pressure was measured, and hypertension was defined as present if systolic blood pressure was  $\geq$  140 mmHg, diastolic blood pressure was  $\geq$  90 mmHg, and/or the patient was on antihypertensive drugs. Blood chemistry parameters, including levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol, fasting blood sugar, insulin, hemoglobin A1C, and creatinine were also measured. Low-density lipoprotein cholesterol was calculated using the Friedewald equation<sup>[22]</sup>. Hyperlipidemia was defined as present if low-density lipoprotein cholesterol was  $\geq$  120 mg/dL and/or on the patient was on medication for the same. Diabetes mellitus was defined as present if fasting blood

**Table 2** Blood chemical parameters (mean  $\pm$  SD)

	NonVSA Group	VSA Group	<i>P</i> value
Total cholesterol (mg/dL)	196 $\pm$ 38	205 $\pm$ 27	NS
Triglyceride (mg/dL)	158 $\pm$ 63	142 $\pm$ 57	NS
HDL-cholesterol (mg/dL)	52 $\pm$ 15	55 $\pm$ 13	NS
LDL-cholesterol (mg/dL)	113 $\pm$ 30	123 $\pm$ 24	NS
Fasting blood sugar (mg/dL)	103 $\pm$ 24	97 $\pm$ 13	NS
Hemoglobin A1C (%)	5.6 $\pm$ 0.8	5.4 $\pm$ 0.6	NS
C-reactive protein (mg/L)	1.8 $\pm$ 2.9	1.6 $\pm$ 3.6	NS

VSA: Vasospastic angina; NS: Not significant; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.

sugar was  $\geq$  126 mg/dL, hemoglobin A1C was  $\geq$  6.5%, and/or the patient was on medication for the same.

#### Statistical analysis

All data are expressed as mean  $\pm$  SD. Baseline characteristics of the 2 groups were compared using the Student's unpaired *t*-test or  $\chi^2$  analysis as appropriate. The Pearson's correlation coefficient was used to investigate the relationship between coronary microvascular parameters and clinical parameters. A *P* value of  $<$  0.05 was considered statistically significant.

## RESULTS

#### Patient characteristics and blood chemistry parameters

Patient characteristics are presented in Table 1. Body mass index (BMI) was significantly lower in the VSA group than in the nonVSA group. The frequency of conventional coronary risk factors and the rate of statin use were similar between the 2 groups. The left ventricular ejection fraction as evaluated by echocardiography was similar between the 2 groups. The duration of angina was 9  $\pm$  2 mo. The results of blood chemistry analysis were similar between the 2 groups (Table 2).

#### Angiographic characteristics of coronary spasms in the VSA group

Although coronary spasm was not induced by ACh infusion at 3  $\mu$ g/min, it was induced by ACh infusion at 30  $\mu$ g/min in 14 patients, EM infusion at 20  $\mu$ g/min in 1 patient, and EM infusion at 30  $\mu$ g/min in 21 patients. Coronary spasm occurred in the proximal segment in 1 patient; proximal and middle segments in 1 patient; middle segment in 14 patients; middle and distal segments in 8 patients; distal segment in 6 patients; and proximal, middle, and distal segments in 6 patients. Therefore, coronary spasm occurred in the distal segments in 20 patients (56%). A focal spasm was identified in 13 patients (36%), while a diffuse spasm was identified in 23 patients (64%). Multivessel coronary spasm occurred in 6 patients (17%).

#### Coronary vasomotion in response to drugs

Low-dose ACh infusion (3  $\mu$ g/min) did not cause coronary spasms; therefore, we adopted the coronary artery response to low-dose ACh as the endothelial-dependent

**Table 3** Quantitative coronary angiography and Doppler flow velocity (mean ± SD)

	NonVSA Group	VSA Group	P value
Heart rate at baseline (/min)	67 ± 13	67 ± 9	NS
Mean arterial pressure (mmHg)	107 ± 11	103 ± 16	NS
Coronary artery diameter (mm)			
Baseline	3.14 ± 0.48	2.95 ± 0.55	NS
Acetylcholine 3 µg/min	3.24 ± 0.55	2.90 ± 0.59	0.013
Nitroglycerin infusion	3.57 ± 0.65	3.43 ± 0.55	NS
Coronary blood flow (mL/min)			
Baseline	94 ± 48	84 ± 69	NS
Acetylcholine 3 µg/min	153 ± 15	130 ± 15	NS
Average peak velocity (cm/s)			
Baseline	21 ± 8	21 ± 12	NS
After ATP infusion	63 ± 25	64 ± 24	NS

VSA: Vasospastic angina; NS: Not significant; ATP: Adenosine triphosphate.

**Table 4** Relationship between clinical parameters and coronary microvascular function (mean ± SD)


Parameters	ACh-induced increase in CBF	P value	CFR	P value
Age (yr)	<i>r</i> = 0.188	NS	<i>r</i> = 0.204	NS
Disease period (mo)	<i>r</i> = -0.016	NS	<i>r</i> = -0.260	NS
Current smoking				
(+, <i>n</i> = 12)	54.5 ± 14.0	NS	3.1 ± 0.6	NS
(-, <i>n</i> = 24)	54.4 ± 9.9		3.3 ± 0.8	
Diffuse spasm				
(+, <i>n</i> = 23)	60.8 ± 49.9	NS	3.2 ± 0.6	NS
(-, <i>n</i> = 13)	43.2 ± 43.3		3.3 ± 0.9	
Distal spasm				
(+, <i>n</i> = 20)	57.0 ± 49.3	NS	3.2 ± 0.7	NS
(-, <i>n</i> = 16)	51.3 ± 47.2		3.3 ± 0.8	
Multi-vessel spasm				
(+, <i>n</i> = 7)	41.8 ± 26.4	NS	3.1 ± 0.7	NS
(-, <i>n</i> = 29)	57.5 ± 51.5		3.3 ± 0.7	

ACh: Acetylcholine; CFR: Coronary flow reserve; NS: Not significant; CBF: Coronary blood flow.

coronary artery parameter. The results of coronary vasomotion in response to each drug are shown in Table 3 and Figures 1 and 2. Heart rate, mean blood pressure, coronary artery diameter, and CBF at baseline did not differ between groups. The change in coronary artery diameter in response to ACh infusion at 3 µg/min was lesser in the VSA group than in the nonVSA group, although NTG-induced coronary artery dilatation was similar between the 2 groups (Table 3 and Figure 1). CFR and CBF increase in response to low-dose ACh infusion did not differ between groups (Table 3 and Figure 2). Neither CFR nor the increase in CBF induced by low-dose ACh was correlated with several clinical factors, including age, duration of angina, smoking status, and presence of diffuse and distal spasms (Table 4).

## DISCUSSION


In the present study, we compared endothelium-independent and -dependent coronary microvascular functions



**Figure 1** Percentage changes in epicardial coronary artery diameter in response to acetylcholine and nitroglycerin infusion. A: Percentage changes in coronary artery diameter in response to low-dose acetylcholine infusion was significantly lower in the vasospastic angina (VSA) group than in the nonVSA group; B: Percentage changes in coronary artery diameter in response to nitroglycerin infusion were similar between groups. NS: Not significant.

between patients with VSA characterized by coronary spasms in LAD and age-matched and sex-matched patients who tested negative in the coronary spasm provocation test. ACh-induced changes in the epicardial coronary arteries were impaired in the VSA group; however, other vascular functions, such as NTG-induced epicardial coronary artery dilatation, CFR, and ACh-induced increase in CBF, were similar between the 2 groups. Coronary endothelial dysfunction at the level of conduit vessels, but not at the level of resistance vessels, may contribute to VSA pathogenesis.

The vascular endothelium is not only a simple passive barrier between the circulating blood and surrounding tissues but also a multifunctional organ, the integrity of which is essential to normal vascular physiology<sup>[25]</sup>. It releases various vasodilators, including nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor, as well as vasoconstrictors. NO plays an important role in the regulation of vascular tone, inhibition of platelet aggregation, and suppression of vascular smooth muscle cell proliferation<sup>[24,25]</sup>. ACh causes vasodilation by releasing NO from the endothelium in healthy humans, whereas it causes vasoconstriction in patients with coronary atherosclerosis<sup>[23,26]</sup>. The coronary arteries in patients



**Figure 2** Percentage changes in coronary blood flow in response to acetylcholine infusion and coronary flow reserve. A: Percentage changes in coronary blood flow in response to low-dose acetylcholine infusion; B: Coronary flow reserve did not differ between the 2 groups. NS: Not significant.

with VSA are highly sensitive to the vasoconstrictive effect of intracoronary ACh infusion, thereby resulting in spasms<sup>[27-29]</sup>. Thus, intracoronary ACh injection is used as a provocative test for coronary spasm<sup>[27-29]</sup>. Therefore, in the present study, we assessed coronary endothelial function using low-dose ACh infusion (3  $\mu$ g/min), which did not cause significant coronary spasms.

Regarding coronary vascular function at the level of conduit vessels, it is accepted that abnormal vascular function of the epicardial coronary arteries is present in VSA patients<sup>[3-7]</sup>, although it has not been clarified whether coronary endothelial dysfunction only, coronary smooth muscle dysfunction only, or both contribute to VSA pathogenesis<sup>[3,5]</sup>. In the present study, low-dose ACh infusion caused significant vasoconstriction in patients with VSA compared with those without, whereas NTG administration did not cause significant differences between groups, suggesting that endothelial dysfunction of the epicardial coronary artery was present in patients with VSA.

Regarding coronary microvascular function in patients with VSA, several studies have investigated the coronary microvascular endothelium-independent function using CFR measurements<sup>[9-12]</sup>. According to these reports<sup>[9-12]</sup>, several clinical factors, including patient age, disease

period, smoking status, and presence of diffuse and distal spasms were associated with decreased CFR. In the present study, CFR in the VSA group was not decreased compared with that in the nonVSA group. In addition, CFR in the VSA group was not associated with any clinical parameter suggested by previous studies<sup>[9-12]</sup>. Our subjects were patients with VSA characterized by coronary spasms in LADs. However, coronary spasms occur in other coronary vessels as well<sup>[30,31]</sup>, and it sometimes occurs prominently in the right coronary artery. Therefore, the assessment of coronary microvascular function only in LADs may be insufficient to determine coronary microvascular function in patients with VSA. Furthermore, the nonVSA group in which patients underwent coronary angiography and spasm provocation tests for the evaluation of chest symptoms may have included patients with microvascular angina. It is well known that coronary microvascular function is impaired in such patients<sup>[32]</sup>. However, if such patients were included in the nonVSA group, CFR in this group would have already been low. Differences in these patient characteristics as well as differences in methodologies and materials, such as the stress agents, their doses, the administration sites (intravenous or intracoronary), and segments in which Doppler flow guidewires are placed, may have led to the differing results.

On the other hand, only few studies have investigated the coronary microvascular endothelium-dependent function. Okumura *et al.*<sup>[8]</sup> showed that CBF significantly increased during coronary spasms in LAD, indicating that the microvascular endothelium-dependent function was preserved. Our results, assessed under the nonspastic status, showed that microvascular endothelial function was not impaired in the VSA group compared with that in the nonVSA group. As mentioned above, it was possible that the microvascular endothelial function was already impaired in the nonVSA group if patients with microvascular angina were included. However, our results showed that coronary microvascular endothelial dysfunction was not involved in the pathogenesis of VSA.

Our results suggest two clinical implications. First, endothelial dysfunction of the epicardial coronary artery, even at the nonspastic segment, was present in patients with VSA. Although endothelial dysfunction may occur throughout the vasculature, the degree of endothelial dysfunction may not always be consistent. Regarding the relationship between the presence of a myocardial bridge and VSA<sup>[53]</sup>, it is possible that local external force may cause the difference in the development of endothelial dysfunction even in the same coronary artery. Therefore, the differences in the degree or development of endothelial dysfunction of the epicardial coronary artery may cause the heterogeneity of occurrence of a coronary spasm. Second, coronary microvascular function may be preserved in patients with VSA to countermeasure myocardial ischemia due to vasospasm of the epicardial coronary artery.

There were several limitations to the present study.

First, as mentioned above, coronary spasms do not always occur in LAD; therefore, our results may not have accounted for all VSA patients. Second, patients in the nonVSA group with chest symptoms, angiographically normal coronary arteries, and a negative spasm provocation test may be heterogeneous; in addition, patients with microvascular angina may have been included in this group. Therefore, it was possible that the nonVSA group was not a pure control. Finally, BMI was not similar between the 2 groups. ACh doses, which were not adjusted according to BMI in the present study, may have contributed to ACh-induced coronary vascular responses. However, coronary artery diameter and CBF at baseline was similar between groups, and we believe that differences in BMI did not affect the coronary vascular responses.

In conclusion, the present study showed that coronary microvascular function, including endothelium-dependent and -independent functions, may be preserved despite coronary endothelial dysfunction at the level of conduit vessels. The latter may contribute to VSA pathogenesis.

## ACKNOWLEDGMENTS

We would like to thank Dr. Junko Soga, Dr. Yuichi Fujii, Dr. Noritaka Fujimura, Dr. Shinsuke Mikami, and Dr. Tatsuya Maruhashi for their help with coronary catheterization. We would also like to thank Ms. Michiko Aoyama, Yuka Shiroshita, and Ryoko Tachiyama for their secretarial assistance.

## COMMENTS

### Background

Vasospastic angina (VSA) is characterized by coronary spasms, which occur because of a dynamic, transient reduction in the luminal diameter of epicardial coronary arteries, leading to myocardial ischemia. It has been reported that abnormal vascular functions of the epicardial coronary arteries were involved in the pathogenesis of VSA. However, coronary microvascular function in patients with VSA remains to be elucidated.

### Research frontiers

The pathogenesis of VSA remains to be unclear. Therefore, to assess coronary vascular response, especially at the level of resistance vessels, may, in part, contribute to the pathogenesis of VSA.

### Innovations and breakthroughs

Several studies investigating coronary vascular function in patients with VSA have been reported and their results have identified coronary vascular dysfunction at the level of the conduit vessels. However, it has not been clarified whether coronary endothelial dysfunction only, coronary smooth muscle dysfunction only, both contribute to VSA pathogenesis. Furthermore, only a few studies have investigated coronary microvascular functions in patients with VSA. In the present study, the authors assessed coronary vascular functions using quantitative coronary angiography and Doppler velocity measurements in VSA patients whose coronary spasm occurred in the left anterior descending coronary artery, and compared them with those in nonVSA patients with negative spasm provocation test. The results showed that the change in coronary artery diameter in response to a low dose of acetylcholine (ACh) was lower in the VSA group, whereas nitroglycerin-induced coronary artery dilatation and coronary blood flow increase in response to ACh or coronary flow reserve did not differ significantly between the 2 groups. These findings suggest that microvascular coronary function may be preserved despite endothelial dysfunction of the epicardial coronary arteries in patients with VSA.

## Applications

The results suggest two clinical implications. First, endothelial dysfunction of the epicardial coronary artery was present in patients with VSA. Second, coronary microvascular functions including endothelium-dependent and may be preserved in patients with VSA. Such coronary vascular response may highlight the pathogenesis of VSA. In addition, the latter finding may countermeasure myocardial ischemia due to vasospasm of the epicardial coronary artery.

## Terminology

Regarding coronary vascular functions, there are two components: at the level of conduit vessels (epicardial coronary artery) and at the level of resistance vessels (microvascular coronary artery). In addition, regarding the factors of coronary artery vasodilation, there are two factors: endothelium-dependent and -independent ones. In the present study, using quantitative coronary angiography and Doppler velocity measurements, the authors defined the percent changes in epicardial coronary diameter in response to ACh and NTG infusions as the endothelium-dependent and -independent functions of the coronary artery at the level of conduit vessels, and defined the percent change in coronary blood flow in response to ACh infusion and coronary flow reserve as the endothelium-dependent and -independent functions of the coronary artery at the level of resistance vessels.

## Peer review

The results presented in this paper are good, with the references are properly Quoted and work is new. The paper is very well organized and the results presented in this paper are justified, and the paper may be accepted in the format in which it is submitted, with the references listed.

## REFERENCES

- 1 **Yasue H**, Kugiyama K. Coronary spasm: clinical features and pathogenesis. *Intern Med* 1997; **36**: 760-765 [PMID: 9392345 DOI: 10.2169/internalmedicine.36.760]
- 2 **Hung MJ**. Current advances in the understanding of coronary vasospasm. *World J Cardiol* 2010; **2**: 34-42 [PMID: 21160682 DOI: 10.4330/wjc.v2.i2.34]
- 3 **Kugiyama K**, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M, Inobe Y, Hirashima O, Kawano H, Soejima H, Yasue H. Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. *J Am Coll Cardiol* 1997; **30**: 920-926 [PMID: 9316519 DOI: 10.1016/S0735-1097(97)00236-2]
- 4 **Fukuda Y**, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. *Circ J* 2002; **66**: 58-62 [PMID: 11999667 DOI: 10.1253/circj.66.58]
- 5 **Egashira K**, Inou T, Yamada A, Hirooka Y, Takeshita A. Preserved endothelium-dependent vasodilation at the vasospastic site in patients with variant angina. *J Clin Invest* 1992; **89**: 1047-1052 [PMID: 1371774 DOI: 10.1172/JCI115646]
- 6 **Shimokawa H**, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. *Cardiovasc Res* 1999; **43**: 1029-1039 [PMID: 10615430 DOI: 10.1016/S0008-6363(99)00144-3]
- 7 **Masumoto A**, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. *Circulation* 2002; **105**: 1545-1547 [PMID: 11927519 DOI: 10.1161/hc1302.105938]
- 8 **Okumura K**, Yasue H, Matsuyama K, Ogawa H, Kugiyama K, Sakaino N, Yamabe H, Morita E. A study on coronary hemodynamics during acetylcholine-induced coronary spasm in patients with variant angina: endothelium-dependent dilation in the resistance vessels. *J Am Coll Cardiol* 1992; **19**: 1426-1434 [PMID: 1593035 DOI: 10.1016/0735-1097(92)90598-H]

- 9 **Akasaka T**, Yoshida K, Hozumi T, Takagi T, Kawamoto T, Kaji S, Morioka S, Yoshikawa J. Comparison of coronary flow reserve between focal and diffuse vasoconstriction induced by ergonovine in patients with vasospastic angina. *Am J Cardiol* 1997; **80**: 705-710 [PMID: 9315573 DOI: 10.1016/S0002-9147(97)00499-2]
- 10 **Anzai H**, Saijo T, Nakajima R, Tezuka N, Takagi T, Tsunoda T, Kobayashi N, Nakamura S, Yamaguchi T. [Evaluation of coronary flow reserve in patients with vasospastic angina]. *J Cardiol* 2000; **36**: 17-27 [PMID: 10929262]
- 11 **Sueda S**, Kohno H, Fukuda H, Uraoka T. Coronary flow reserve in patients with vasospastic angina: correlation between coronary flow reserve and age or duration of angina. *Coron Artery Dis* 2003; **14**: 423-429 [PMID: 12966262 DOI: 10.1097/01.mca.0000085705.34267.e2]
- 12 **Ashikaga T**, Nishizaki M, Fujii H, Niki S, Maeda S, Yamawake N, Kishi Y, Isobe M. Examination of the microcirculation damage in smokers versus nonsmokers with vasospastic angina pectoris. *Am J Cardiol* 2007; **100**: 962-964 [PMID: 17826378 DOI: 10.1016/j.amjcard.2007.04.035]
- 13 **Matsuda K**, Teragawa H, Fukuda Y, Ueda K, Higashi Y, Sakai K, Miura F, Hirao H, Yamagata T, Yoshizumi M, Chayama K. Response of the left anterior descending coronary artery to acetylcholine in patients with chest pain and angiographically normal coronary arteries. *Am J Cardiol* 2003; **92**: 1394-1398 [PMID: 14675572 DOI: 10.1016/j.amjcard.2003.08.043]
- 14 **Teragawa H**, Fukuda Y, Matsuda K, Ueda K, Higashi Y, Oshima T, Yoshizumi M, Chayama K. Relation between C reactive protein concentrations and coronary microvascular endothelial function. *Heart* 2004; **90**: 750-754 [PMID: 15201242 DOI: 10.1136/hrt.2003.022269]
- 15 **Teragawa H**, Ueda K, Matsuda K, Kimura M, Higashi Y, Oshima T, Yoshizumi M, Chayama K. Relationship between endothelial function in the coronary and brachial arteries. *Clin Cardiol* 2005; **28**: 460-466 [PMID: 16274093 DOI: 10.1002/clc.4960281004]
- 16 **Teragawa H**, Mitsuba N, Nishioka K, Ueda K, Kono S, Higashi Y, Chayama K, Kihara Y. Impaired coronary microvascular endothelial function in men with metabolic syndrome. *World J Cardiol* 2010; **2**: 205-210 [PMID: 21160752 DOI: 10.4330/wjc.v2.i7.205]
- 17 **Teragawa H**, Kato M, Yamagata T, Matsuura H, Kajiyama G. Magnesium causes nitric oxide independent coronary artery vasodilation in humans. *Heart* 2001; **86**: 212-216 [PMID: 11454846 DOI: 10.1136/heart.86.2.212]
- 18 **JCS Joint Working Group**. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. *Circ J* 2010; **74**: 1745-1762 [PMID: 20671373]
- 19 **Shiode N**, Morishima N, Nakayama K, Yamagata T, Matsuura H, Kajiyama G. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. *J Am Coll Cardiol* 1996; **27**: 304-310 [PMID: 8557898 DOI: 10.1016/0735-1097(95)00465-3]
- 20 **Shiode N**, Nakayama K, Morishima N, Yamagata T, Matsuura H, Kajiyama G. Nitric oxide production by coronary conductance and resistance vessels in hypercholesterolemia patients. *Am Heart J* 1996; **131**: 1051-1057 [PMID: 8644581 DOI: 10.1016/S0002-8703(96)90076-9]
- 21 **Kato M**, Shiode N, Yamagata T, Matsuura H, Kajiyama G. Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis. *Heart* 1997; **78**: 493-498 [PMID: 9415011 DOI: 10.1136/hrt.78.5.493]
- 22 **Friedewald WT**, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499-502 [PMID: 4337382]
- 23 **Rubanyi GM**. The role of endothelium in cardiovascular homeostasis and diseases. *J Cardiovasc Pharmacol* 1993; **22** Suppl 4: S1-14 [PMID: 7523767]
- 24 **Vallance P**, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. *Lancet* 1989; **2**: 997-1000 [PMID: 2572793 DOI: 10.1016/S0140-6736(89)91013-1]
- 25 **Vanhoutte PM**. Endothelium and control of vascular function. State of the Art lecture. *Hypertension* 1989; **13**: 658-667 [PMID: 2661425 DOI: 10.1161/01.HYP.13.6.658]
- 26 **Furchgott RF**, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980; **288**: 373-376 [PMID: 6253831 DOI: 10.1038/288373a0]
- 27 **Yasue H**, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. *Circulation* 1986; **74**: 955-963 [PMID: 3769179 DOI: 10.1161/01.CIR.74.5.955]
- 28 **Okumura K**, Yasue H, Horio Y, Takaoka K, Matsuyama K, Kugiyama K, Fujii H, Morikami Y. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. *Circulation* 1988; **77**: 535-542 [PMID: 3342484 DOI: 10.1161/01.CIR.77.3.535]
- 29 **Yasue H**, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm—clinical features, diagnosis, pathogenesis, and treatment. *J Cardiol* 2008; **51**: 2-17 [PMID: 18522770 DOI: 10.1016/j.jjcc.2008.01.001]
- 30 **Sueda S**, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T. Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. *Coron Artery Dis* 2003; **14**: 451-457 [PMID: 12966266 DOI: 10.1097/01.mca.0000085706.34267.39]
- 31 **Takagi Y**, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura SI, Ogawa H, Shimokawa H. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: Multicentre Registry Study of the Japanese Coronary Spasm Association. *Eur Heart J* 2013; **34**: 258-267 [PMID: 22782943 DOI: 10.1093/eurheartj/ehs199]
- 32 **Kaski JC**. Overview of gender aspects of cardiac syndrome X. *Cardiovasc Res* 2002; **53**: 620-626 [PMID: 11861032 DOI: 10.1016/S0008-6363(01)00460-6]
- 33 **Teragawa H**, Fukuda Y, Matsuda K, Hirao H, Higashi Y, Yamagata T, Oshima T, Matsuura H, Chayama K. Myocardial bridging increases the risk of coronary spasm. *Clin Cardiol* 2003; **26**: 377-383 [PMID: 12918640 DOI: 10.1002/clc.4950260806]

P- Reviewers Hardt S, Fineschi V, Chawla M  
S- Editor Song XX L- Editor A E- Editor Zhang DN



**GENERAL INFORMATION**

*World Journal of Cardiology* (*World J Cardiol*, *WJC*, online ISSN 1949-8462, DOI: 10.4330) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

**Aim and scope**

*WJC* covers topics concerning arrhythmia, heart failure, vascular disease, stroke, hypertension, prevention and epidemiology, dyslipidemia and metabolic disorders, cardiac imaging, pediatrics, nursing, and health promotion. Priority publication will be given to articles concerning diagnosis and treatment of cardiology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJC*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

*WJC* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

**Columns**

The columns in the issues of *WJC* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in

Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in cardiology; (12) Brief Articles: To briefly report the novel and innovative findings in cardiology; (13) Meta-Analysis: To evaluate the clinical effectiveness in cardiology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJC*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of cardiology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

**Name of journal**

*World Journal of Cardiology*

**ISSN**

ISSN 1949-8462 (online)

**Launch date**

December 31, 2009

**Frequency**

Monthly

**Editor-in-Chief**

**Raúl Moreno, MD, Director** of Interventional Cardiology, Interventional Cardiology, Hospital La Paz, Paseo La Castellana, 261,

## Instructions to authors

28041 Madrid, Spain

**Victor L Serebruany, MD, PhD, Associate Professor**, Johns Hopkins University School of Medicine, President, HeartDrug™ Research Laboratories, Osler Medical Center, 7600 Osler Drive, Suite 307, Towson, MD 21204, United States

### Editorial office

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Cardiology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-59080039  
Fax: +86-10-85381893  
E-mail: wjc@wjgnet.com  
<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Telephone: +852-58042046  
Fax: +852-31158812  
E-mail: bpgoffice@wjgnet.com  
<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893

### Representative office

USA Office  
8226 Regency Drive,  
Pleasanton, CA 94588-3144, United States

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/1949-8462/g\\_info\\_20100316161927.htm](http://www.wjgnet.com/1949-8462/g_info_20100316161927.htm).

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now

available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1949-8462/g\\_info\\_20100316161927.htm](http://www.wjgnet.com/1949-8462/g_info_20100316161927.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjc@wjgnet.com](mailto:wjc@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province,

country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomerybissell@ucsf.edu](mailto:montgomerybissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any

## Instructions to authors

footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic

effect of Jianpi Yishen decoction in treatment of Pixu-diarthra. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.00000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

**Statistical data**

Write as mean  $\pm$  SD or mean  $\pm$  SE.

**Statistical expression**

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Units**

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/1949-8462/g\\_info\\_20100312200347.htm](http://www.wjgnet.com/1949-8462/g_info_20100312200347.htm).

**Abbreviations**

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

**Italics**

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

**Examples for paper writing**

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

**RESUBMISSION OF THE REVISED MANUSCRIPTS**

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The

revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

**Language evaluation**

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

**Copyright assignment form**

Please download a Copyright assignment form from [http://www.wjgnet.com/1949-8462/g\\_info\\_20100312200118.htm](http://www.wjgnet.com/1949-8462/g_info_20100312200118.htm).

**Responses to reviewers**

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1949-8462/g\\_info\\_20100312195923.htm](http://www.wjgnet.com/1949-8462/g_info_20100312195923.htm).

**Proof of financial support**

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

**Links to documents related to the manuscript**

WJG will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

**Publication fee**

WJG is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Room 1701, 17/F, Henan Building,

No. 90 Jaffe Road, Wanchai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

